On June 9, WuXi XDC fell 3.59% in regular trading, trading at HK$44.94/share, with trading volume of HK$46.07 million. The stock has now dropped over 21% below its recent buyback average price of HK$57.3, signaling deepening weakness.

On the news front, the company previously disclosed that its professional trustee repurchased 5.702 million shares at an average price of HK$57.3, totaling approximately HK$327 million. Parent company WuXi Biologics also has a buyback plan of up to US$400 million, bringing the WuXi group total repurchase scale to US$500 million. Despite this intensive buyback campaign, selling pressure remains dominant and the stock continues to decline.

Within the Life Sciences Tools and Services sector, the entire WuXi group came under broad pressure. WuXi Biologics fell 4.81%, WuXi AppTec fell 4.7%, GenScript Biotech fell 4.3%, XtalPi fell 3.1%, and Insilico fell 2.01%, reflecting persistent sector-wide headwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)